Discover why Rigel Pharma (RIGL) is a contrarian biotech BUY with surging revenues, strong drug sales, and 20-30% upside ...

Rigel Pharmaceuticals, Inc. posted a solid Q3 with robust sales growth. Discover insights on future profitability and market ...

Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and ...

Have you been paying attention to shares of Rigel Pharmaceuticals (RIGL)? Shares have been on the move with the stock up 73.3% over the past month. The stock hit a new 52-week high of $51.73 in the ...

Four months ago, Rigel Pharmaceuticals spent just $2 million—plus ponying up another $233 million in potential milestones—to acquire Forma Therapeutics’ leukemia drug Rezlidhia. On Thursday, Rigel got ...

Shares of Rigel Pharmaceuticals RIGL have rallied 76.7% in the past three months. This stock price rally can be attributed to growing investor confidence regarding the strong growth of the company’s ...

R343 is an inhaled SYK inhibitor, being developed for the treatment of patients suffering from allergic asthma. In Sep 2012, Rigel had initiated the phase II, double-blind, multi-center study (n=270) ...

Company Expects Trial Results to Lead to Enhanced Economics, Trims Research Efforts SOUTH SAN FRANCISCO, Calif., Feb. 3 -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that it will delay ...

As Roche officially abandoned cancer drug Gavreto, its former partner Blueprint Medicines has found the RET inhibitor a new owner in the U.S. Rigel Pharmaceuticals will pay Blueprint $15 million to ...

The biotechnology company is hoping to improve coronavirus care. Imperial College London will conduct the trial to evaluate the efficacy of fostamatinib for the treatment of COVID-19 pneumonia.